APLS(Delisted)
Apellis·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APLS
Apellis Pharmaceuticals, Inc.
A commercial-stage biopharmaceutical company focused on the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade
100 Fifth Avenue
, Waltham
, MA 02451
Discovers, develops and commercializes complement system inhibitors.
Apellis Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on September 25, 2009. The Company is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds for the treatment of diseases with high unmet need by inhibiting the complement system (as a component of the immune system) at the level of central protein C3 in the complement cascade. In February 2023, the U.S. Food and Drug Administration (FDA) approved SYFOVRE, the first drug approved for the treatment of geographic atrophy secondary to age-related macular degeneration (GA).
Company Financials
EPS
APLS has released its 2025 Q4 earnings. EPS was reported at 0.47, versus the expected -0.38, beating expectations. The chart below visualizes how APLS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
APLS has released its 2026 Q1 earnings report, with revenue of 268.30M, reflecting a YoY change of 60.85%, and net profit of 18.66M, showing a YoY change of 120.23%. The Sankey diagram below clearly presents APLS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
